

- disease. A cost-effectiveness analysis. *Ann Intern Med* 119(6):503-509, 1993.
737. Fix AD, Strickland GT, Grant J. Tick bites and Lyme disease in an endemic setting: problematic use of serologic testing and prophylactic antibiotic therapy. *JAMA* 279(3):206-210, 1998.
 738. Guy EC, Robertson JN, Cimmino M, et al. European interlaboratory comparison of Lyme borreliosis serology. *Zentralbl Bakteriol* 287(3):241-247, 1998.
 739. Bakken LL, Callister SM, Wand PJ, Schell RF. Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program. *J Clin Microbiol* 35(3):537-543, 1997.
 740. Dayian G, Morse DL, Schryver GD, et al. Implementation of a proficiency testing program for Lyme disease in New York State. *Arch Pathol Lab Med* 118(5):501-505, 1994.
 741. Craven RB, Quan TJ, Bailey RE, et al. Improved serodiagnostic testing for Lyme disease: results of a multicenter serologic evaluation. *Emerg Infect Dis* 2(2):136-140, 1996.
 742. Rose CD, Fawcett PT, Singsen BH, et al. Use of Western blot and enzyme-linked immunosorbent assays to assist in the diagnosis of Lyme disease. *Pediatrics* 88:465, 1991.
 743. Weiss NL, Sadock VA, Sigal LH, et al. False positive seroreactivity to *Borrelia burgdorferi* in systemic lupus erythematosus: the value of immunoblot analysis. *Lupus* 4(2):131-137, 1995.
 744. Fatehnejad S, Filkrig MK, Rahn DW, Malawista SE. Parvovirus arthritis mistaken for Lyme arthritis. *J Rheumatol* 19:1002, 1992.
 745. Kaell AT, Redecha PR, Elkon KB, et al. Occurrence of antibodies to *Borrelia burgdorferi* in patients with nonspirochetal subacute bacterial endocarditis. *Ann Intern Med* 119(11):1079-1083, 1993.
 746. Hansen K, Pii K, Lebech A-M. Improved immunoglobulin M serodiagnosis in Lyme borreliosis by using a μ -capture enzyme-linked immunosorbent assay with biotinylated *Borrelia burgdorferi* flagella. *J Clin Microbiol* 29:166-173, 1991.
 747. Wormser GP, Horowitz HW, Nowakowski J, et al. Positive Lyme disease serology in patients with clinical and laboratory evidence of human granulocytic ehrlichiosis. *Am J Clin Pathol* 107(2):142-147, 1997.
 748. Tugwell P, Dennis DT, Weinstein A, et al. Guidelines for laboratory evaluation in the diagnosis of Lyme disease. American College of Physicians. *Ann Intern Med* 127(12):1106-1108, 1997.
 749. Association of State and Territorial Public Health Laboratory Directors and the Centers for Disease Control and Prevention. Recommendations. In *Proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease* (Dearborn, MI). Washington, DC, Association of State and Territorial Public Health Laboratory Directors, 1995, pp 1-5.
 750. Golightly MG. Lyme borreliosis: laboratory considerations. *Semin Neurol* 17(1):11-17, 1997.
 751. Steere AC, Grodzicki RL, Craft JE, et al. Recovery of Lyme disease spirochetes from patients. *Yale J Biol Med* 57:557, 1984.
 752. Berger BW, Johnson RC, Kodner C, Coleman L. Cultivation of *Borrelia burgdorferi* from human tick bite sites: a guide to the risk of infection. *J Am Acad Dermatol* 32(2 Pt 1):184-187, 1995.
 753. Wienecke R, Neubert U, Volkenandt M. Molecular detection of *Borrelia burgdorferi* in formalin-fixed, paraffin-embedded lesions of Lyme disease. *J Cutan Pathol* 20(5):385-388, 1993.
 754. Schmidt BL, Aberer E, Stockenhuber D, et al. Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in the urine and breast milk of patients with Lyme borreliosis. *Diagn Microbiol Infect Dis* 21(3):121-128, 1995.
 755. Priem S, Rittig MG, Kamradt T, et al. An optimized PCR leads to rapid and highly sensitive detection of *Borrelia burgdorferi* in patients with Lyme borreliosis. *J Clin Microbiol* 35(3):685-690, 1997.
 756. Brunner M, Stein S, Mitchell PD, Sigal LH. Immunoglobulin M capture assay for serologic confirmation of early Lyme disease: analysis of immune complexes with biotinylated *Borrelia burgdorferi* sonicate enhanced with flagellin peptide epitope. *J Clin Microbiol* 36(4):1074-1080, 1998.
 757. Berardi VP, Weeks KE, Steere AC. Serodiagnosis of early Lyme disease: analysis of IgM and IgG antibody responses by using an antibody-capture enzyme immunoassay. *J Infect Dis* 158:754, 1988.
 758. Magnarelli LA, Anderson JF, Johnson RC. Cross-reactivity in serological tests for Lyme disease and other spirochetal infections. *J Infect Dis* 156:183, 1987.
 759. Hilton E, Devoti J, Sood S. Recommendation to include OspA and OspB in the new immunoblotting criteria for serodiagnosis of Lyme disease [published erratum appears in *J Clin Microbiol* 1997 October; 35(10):2713]. *J Clin Microbiol* 34(6):1353-1354, 1996.
 760. Bunikis J, Olsen B, Westman G, Bergstrom S. Variable serum immunoglobulin responses against different *Borrelia burgdorferi* sensu lato species in a population at risk for and patients with Lyme disease. *J Clin Microbiol* 33(6):1473-1478, 1995.
 761. Norman GL, Antig JM, Bigaignon G, Hogrefe WR. Serodiagnosis of Lyme borreliosis by *Borrelia burgdorferi* sensu stricto, *B. garinii*, and *B. afzelii* western blots (immunoblots). *J Clin Microbiol* 34(7):1732-1738, 1996.
 762. Rath PM, Marsch WC, Brade V, Fehrenbach F. Serological distinction between syphilis and Lyme borreliosis. *Zentralbl Bakteriol* 280(3):319-324, 1994.
 763. Rose CD, Fawcett PT, Gibney KM, Doughty RA. The overdiagnosis of Lyme disease in children residing in an endemic area. *Clin Pediatr* 33(11):663-668, 1994.
 764. Fawcett PT, Rose CD, Gibney KM, Doughty RA. Correlation of seroreactivity with response to antibiotics in pediatric Lyme borreliosis. *Clin Diagn Lab Immunol* 4(1):85-88, 1997.
 765. Huppertz HI, Mosbauer S, Busch DH, Karch H. Lymphoproliferative responses to *Borrelia burgdorferi* in the diagnosis of Lyme arthritis in children and adolescents. *Eur J Pediatr* 155(4):297-302, 1996.
 766. Quan TJ, Wilmoth BA, Carter LG, Bailey RE. A comparison of some commercially available serodiagnostic kits for Lyme disease. In *Proceedings of the First National Conference on Lyme Disease Testing* (Dearborn, MI). Washington, DC, Association of State and Territorial Public Health Laboratory Directors, 1991, pp 61-73.
 767. Reid MC, Schoen RT, Evans J, et al. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. *Ann Intern Med* 128(5):354-362, 1998.
 768. Feder HM Jr, Hunt MS. Pitfalls in the diagnosis and treatment of Lyme disease in children. *JAMA* 274(1):66-68, 1995.
 769. Hsu VM, Patella SJ, Sigal LH. "Chronic Lyme disease" as the incorrect diagnosis in patients with fibromyalgia. *Arthritis Rheum* 36(11):1493-1500, 1993.

770. Sigal LH. Summary of the first 100 patients seen at a Lyme referral center. *Am J Med* 88:577-581, 1990.
771. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. *Ann Intern Med* 99:767, 1983.
772. Jung PI, Nahas JN, Strickland GT, et al. Maryland physicians' survey on Lyme disease. *Maryland Med J* 43(5):447-450, 1994.
773. Eppes SC, Klein JD, Caputo GM, et al. Physician beliefs, attitudes, and approaches toward Lyme disease in an endemic area. *Clin Pediatr* 33(3):130-134, 1994.
774. Ziska MH, Donta ST, Demarest FC. Physician preferences in the diagnosis and treatment of Lyme disease in the United States. *Infection* 24(2):182-186, 1996.
775. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis—randomised comparison of ceftriaxone and penicillin. *Lancet* 1:1191, 1988.
776. Hassler D, Zoller L, Haude M, et al. Cefotaxime versus penicillin in the late stage of Lyme disease—prospective, randomized therapeutic study. *Infection* 18:16, 1990.
777. Cooper JD, Schoen RT, Malawista SE. Treatment of asymptomatic, retrospectively diagnosed Lyme disease: comment on the report by Christian. *Arthritis Rheum* 36:1637-1638, 1993.
778. Millner MM, Thalhammer GH, Dittrich P, et al. Beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary results. *Infection* 24(2):174-177, 1996.
779. Karlsson M, Hammers S, Nilsson-Ehle I, et al. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. *Antimicrob Agents Chemother* 40(5):1104-1107, 1996.
780. Wormser GP. Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination. *Semin Neurol* 17(1):45-52, 1997.
781. Maloy AL, Black RD, Segurolo RJ, Jr. Lyme disease complicated by the Jarisch-Herxheimer reaction. *J Emerg Med* 16(3):437-438, 1998.
782. Dattwyler RJ, Volkman DJ, Conaty SM, et al. Amoxicillin plus probenecid versus doxycycline for treatment of EM borreliosis. *Lancet* 336:1404, 1990.
783. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. *Ann Intern Med* 117:273, 1992.
784. Luger SW, Pappone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. *Antimicrob Agents Chemother* 39(3):661-667, 1995.
785. Weber K, Preac-Mursic V, Wilske B, et al. A randomized trial of ceftriaxone versus oral penicillin for the treatment of early European Lyme borreliosis. *Infection* 18:91, 1990.
786. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med* 337(5):289-294, 1997.
787. Genese C, Fineli L, Parkin W, Spitalny KC. From the Centers for Disease Control and Prevention. Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease—New Jersey, 1990-1992. *JAMA* 269(8):979-980, 1993.
788. Ettestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. *J Infect Dis* 171(2):356-361, 1995.
789. Kuiper H, de Jongh BM, van Dam AP, et al. Evaluation of central nervous system involvement in Lyme borreliosis patients with a solitary erythema migrans lesion. *Eur J Clin Microbiol Infect Dis* 13(5):379-387, 1994.
790. Wang TJ, Sangha O, Phillips CB, et al. Outcomes of children treated for Lyme disease. *J Rheumatol* 25(11):2249-2253, 1998.
791. National Institute of Arthritis and Musculoskeletal and Skin Disease, and National Institute of Allergy and Infectious Disease. Diagnosis and treatment of Lyme disease, N.I.H. State-of-the-Art Conference. *Clin Courier* 9(5):1, 1991.
792. Schoen RT, Aversa JM, Rahn DW, Steere AC. Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. *Arthritis Rheum* 34:1056, 1991.
793. Smith LG, Jr, Pearlman M, Smith LG, Faro S. Lyme disease: a review with emphasis on the pregnant woman. *Obstet Gynecol Surv* 46:125, 1991.
794. Pal GS, Baker JT, Wright DJM. Penicillin-resistant *Borrelia* encephalitis responding to cefotaxime. *Lancet* 1:50, 1988.
795. Diringner MN, Halperin JJ, Dattwyler RJ. Lyme meningoencephalitis: report of a severe, penicillin-resistant case. *Arthritis Rheum* 30:705, 1987.
796. Hassler D, Riedel K, Zorn J, Preac-Mursic V. Pulsed high-dose cefotaxime therapy in refractory Lyme borreliosis. *Lancet* 338:193, 1991.
797. American Academy of Neurology. Practice parameter: Diagnosis of patients with nervous system Lyme borreliosis (Lyme disease)—Summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 46(3):881-882, 1996.
798. Berger BW. Antibiotic treatment for pregnant victims of Lyme disease. *J Am Acad Dermatol* 24:663, 1991.
799. Williams CL, Strobino BA. Lyme disease transmission during pregnancy. *Contemp Obstet Gynecol* 6:48, 1990.
800. American College of Obstetricians and Gynecologists (ACOG). Lyme disease during pregnancy. ACOG Committee Opinion: Committee on Obstetrics: Maternal and Fetal Medicine. *Int J Gynaecol Obstet* 39:59, 1992.
801. Edly SJ. Lyme disease in pregnancy. *N J Med* 87:557, 1990.
802. Cartter ML, Hadler JL, Gerber MA, Mofenson L. Lyme disease and pregnancy. *Conn Med* 53:341, 1989.
803. Plotkin SA, Peter G, Easton JG, et al. Treatment of Lyme borreliosis. *Pediatrics* 88:176, 1991.
804. Segura-Porta F, Fernandez MM. Treatment of borreliosis. *Enferm Infecc Microbiol Clin* 16(5):239-244, 1998.
805. Silver HM. Lyme disease during pregnancy. *Infect Dis Clin North Am* 11(1):93-97, 1997.
806. Nadelman RB, Wormser GP. Lyme borreliosis. *Lancet* 352(9127):557-565, 1998.
807. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. *Ann Intern Med* 114:472, 1991.
808. Kramer MD, Hassler D, Hofmann H, et al. Therapy of Lyme borreliosis. *Dtsch Med Wochenschr* 118(13):469-473, 1993.
809. Maiwald M. Lyme borreliosis—an infectious disease with interdisciplinary demands. *Tierarztl Prax* 22(4):301-308, 1994.
810. Adams WV, Rose DC, Eppes SC, Klein JD. Cognitive effects of Lyme disease in children. *Pediatrics* 94(2 Pt 1):185-189, 1994.
811. Weber K. Treatment failure in erythema migrans: a review. *Infection* 24:73-75, 1996.
812. Caraco T, Gardner G, Maniatty W, et al. Lyme disease: self-regulation and pathogen invasion. *J Theor Biol* 193(4):561-575, 1998.

813. Schulze TL, Jordan RA, Vasvary LM, et al. Suppression of *Ixodes scapularis* (Acari: Ixodidae) nymphs in a large residential community. *J Med Entomol* 31(2):206-211, 1994.
814. Wormser GP. Prospects for a vaccine to prevent Lyme disease in humans. *Clin Infect Dis* 21(5):1267-1274, 1995.
815. Foley DM, Wang YP, Wu XY, et al. Acquired resistance to *Borrelia burgdorferi* infection in the rabbit. Comparison between outer surface protein A vaccine- and infection-derived immunity. *J Clin Invest* 99(8):2030-2035, 1997.
816. Gondolf KB, Mihatsch M, Curschellas E, et al. Induction of experimental allergic arthritis with outer surface proteins of *Borrelia burgdorferi*. *Arthritis Rheum* 37:1070-1077, 1994.
817. Preac-Mursic V, Patsouris E, Wilske B, et al. Persistence of *Borrelia burgdorferi* and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human disease. *Infection* 18:332, 1990.
818. Johnson RC, Kodner C, Russell M. Passive immunization of hamsters against experimental infection with Lyme disease spirochete. *Infect Immun* 53:713-714, 1986.
819. Sonnesyn SW, Manivel JC, Johnson RC, Goodman JL. A guinea pig model for Lyme disease. *Infect Immun* 61:4777-4784, 1993.
820. England JD, Bohm RP Jr, Roberts ED, Philipp MT. Lyme neuroborreliosis in the rhesus monkey. *Semin Neurol* 17(1):53-56, 1997.
821. Pachner AR, Delaney E, O'Neill T. Neuroborreliosis in the nonhuman primate: *Borrelia burgdorferi* persists in the central nervous system. *Ann Neurol* 38:667-669, 1995.
822. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice against the Lyme disease agent by immunization with recombinant OspA. *Science* 250:553, 1990.
823. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Protection of mice from Lyme borreliosis by oral vaccination with *Escherichia coli* expressing OspA. *J Infect Dis* 164:1224, 1991.
824. Nguyen TP, Lam TT, Barthold SW, et al. Partial destruction of *Borrelia burgdorferi* within ticks that engorged on OspE- or OspF-immunized mice. *Infect Immun* 62(5):2079-2084, 1994.
825. Probert WS, Lefebvre RB. Protection of C3H/HeN mice from challenge with *Borrelia burgdorferi* through active immunization of OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. *Infect Immun* 62:1920-1926, 1994.
826. Telford SR 3rd, Kantor FS, Lobet Y, et al. Efficacy of human Lyme disease vaccine formulations in a mouse model. *J Infect Dis* 171(5):1368-1370, 1995.
827. Fikrig E, Telford SR III, Wallich R, et al. Vaccination against Lyme disease caused by diverse *Borrelia burgdorferi*. *J Exp Med* 181:215-221, 1995.
828. Shih CM, Liu LP. Differential efficacy of passive immunization against infection by Lyme disease spirochetes transmitted by partially fed vector ticks. *J Med Microbiol* 47(9):773-779, 1998.
829. Gern L, Schaible UE, Simon MM. Mode of inoculation of the Lyme disease agent *Borrelia burgdorferi* influences infection and immune responses in inbred strains of mice. *J Infect Dis* 167:971-976, 1993.
830. Mather TN, Telford SR III, Adler GH. Absence of transplacental transmission of Lyme disease spirochetes from reservoir mice (*Peromyscus leucopus*) to their offspring. *J Infect Dis* 164:564, 1991.
831. Burgess EC, Wachal MD, Cleven TD. *Borrelia burgdorferi* infection in dairy cows, rodents, and birds from four Wisconsin dairy farms. *Vet Microbiol* 35(1-2):61-77, 1993.
832. Moody KD, Barthold SW. Relative infectivity of *Borrelia burgdorferi* in Lewis rats by various routes of inoculation. *Am J Trop Med Hyg* 44:135, 1991.
833. Burgess EC. *Borrelia burgdorferi* infection in Wisconsin horses and cows. *Ann N Y Acad Sci* 539:235, 1988.
834. Gustafson JM, Burgess EC, Wachal MD, Steinberg H. Intrauterine transmission of *Borrelia burgdorferi* in dogs. *Am J Vet Res* 54(6):882-890, 1993.
835. Keller D, Koster FT, Marks DH, et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. *J Am Med Assoc* 271:1764-1768, 1994.
836. Schoen RT, Meurice F, Brunet CM, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. *J Infect Dis* 172(5):1324-1329, 1995.
837. Wormser GP, Nowakowski J, Nadelman RB, et al. Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State. *Infection* 26(4):208-212, 1998.
838. Van Hoescke C, Comberbach M, De Grave D, et al. Evaluation of the safety, reactogenicity and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. *Vaccine* 14(17-18):1620-1626, 1996.
839. Van Hoescke C, Fu D, De Grave D, et al. Clinical and immunological assessment of a candidate Lyme disease vaccine in healthy adults: antibody persistence and effect of a booster dose at month 12. *Vaccine* 16(17):1688-1692, 1998.
840. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant *Borrelia burgdorferi* outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. *N Engl J Med* 339(4):216-222, 1998 [erratum 339(8):571, 1998].
841. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant *Borrelia burgdorferi* outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. *N Engl J Med* 339(4):209-215, 1998.
842. Centers for Disease Control and Prevention. Availability of Lyme disease vaccine. *MMWR* 48(2):35-36, 43, 1999.
843. SmithKline Beecham Biologicals. LYMERix product label. Rixensart, Belgium, SmithKline Beecham Biologicals, December 1998.
844. Steigbigel RT, Benach JL. Immunization against Lyme disease—an important first step. *N Engl J Med* 339(4):263-264, 1998.
845. Marwick C. Guarded endorsement for Lyme disease vaccine. *JAMA* 279(24):1937-1938, 1998.
846. Maes E, Lecomte P, Ray N. A cost-of-illness study of Lyme disease in the United States. *Clin Ther* 20(5):993-1008; discussion 992, 1998.
847. Zhang YQ, Mathiesen D, Kolbert CP, et al. *Borrelia burgdorferi* enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection. *J Clin Microbiol* 35(1):233-238, 1997.
848. Brown M, Hebert AA. Insect repellents: an overview. *J Am Acad Dermatol* 36:243-249, 1997.
849. Schwartz B, Warren D. Ticks carrying Lyme disease repelled with two sprays. *NEWS US Dept Agriculture*, April 29, 1985.
850. Hassler D, Maiwald M, Petney TN. Diagnosis, treatment, and prevention of Lyme disease. *JAMA* 280(12):1049-1050; discussion 1051, 1998.

851. Angelov L. Unusual features in the epidemiology of Lyme borreliosis. *Eur J Epidemiol* 12(1):9-11, 1996.
852. Costello CM, Steere AC, Pinkerton RE, Feder HM. A prospective study of tick bites in an endemic area for Lyme disease. *J Infect Dis* 159:136, 1989.
853. Magid D, Schwartz B, Craft J, Schwartz JS. Prevention of Lyme disease after tick bites: a cost-effectiveness analysis. *N Engl J Med* 327:534, 1992.
854. Shapiro ED, Gerber MA, Holabird NB, et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. *N Engl J Med* 327:1769, 1992.
855. Dennis DT, Meltzer MI. Antibiotic prophylaxis after tick bites. *Lancet* 350(9086):1191-1192, 1997.
856. Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. *Am J Dis Child* 147(9):945-947, 1993.
857. Warshafsky S, Nowakowski J, Nadelman RB, et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. *J Gen Intern Med* 11(6):329-333, 1996.
858. Dhote R, Basse-Guerineau AL, Bachmeyer C, et al. Lyme borreliosis: therapeutic aspects. *Presse Med* 27(39):2043-2047, 1998.
859. Melski JW. The many faces and phases of borreliosis. I. Lyme disease. *J Am Acad Dermatol* 24(5 Pt 1):799-801, 1991.
860. Barbour AG. Expert advice and patient expectations: laboratory testing and antibiotics for Lyme disease. *JAMA* 279(3):239-240, 1998.
861. Gray JS, Granstrom M, Cimmino M, et al. Lyme borreliosis awareness. *Zentralbl Bakteriol* 287(3):253-265, 1998.
862. European Union Concerted Action on Lyme Borreliosis. <http://www.dis.strath.ac.uk/vie/LymeEU>
863. Smith-Fiola DC, Hallman WK. Tick bite victims and their environment: the risk of Lyme disease. *N J Med* 92(9):601-603, 1995.
864. Curi MB. Public awareness of Lyme disease in obstetric, pediatric, and student settings in northwestern Connecticut. *Conn Med* 57(10):661-663, 1993.
865. Picken RN, Strle F, Ruzic-Sabljic E, et al. Molecular subtyping of *Borrelia burgdorferi* sensu lato isolates from five patients with solitary lymphocytoma. *J Invest Dermatol* 108(1):92-97, 1997.
866. Kondrat'ev VG, Bykova LA, Poltoratskaia TN, Istratkina SV. The epidemic situation of tick-borne encephalitis and Lyme disease in the city of Tomsk. *Med Parazitol (Mosk)* (1):52-53, 1998.
867. Bondarenko AL, Abbasova SV, Tikhomolova EG, et al. The clinico-epidemiological and laboratory characteristics of the early period of Lyme borreliosis in Kirov Province. *Med Parazitol (Mosk)* (4):18-21, 1997.
868. Matushchenko AA, Rudakova SA, Korenberg EI. The preliminary results of an ecological epidemiological study of Lyme disease in western Siberia. *Med Parazitol (Mosk)* (4):27-29, 1993.
869. Mitchell PD, Reed KD, Aspeslet TL, et al. Comparison of four immunoserologic assays for detection of antibodies to *Borrelia burgdorferi* in patients with culture-positive erythema migrans [published erratum appears in 1994 Sept;32(9):2343]. *J Clin Microbiol* 32(8):1958-1962, 1994.
870. Feder HM Jr, Whitaker DL. Misdiagnosis of erythema migrans. *Am J Med* 99:412-419, 1995.
871. Masters EJ, King LE. Differentiating Loxoscelism from Lyme disease. *Emerg Med* 26(10):47-49, 1994.
872. Dlesk A, Balian AA, Sullivan BJ, et al. Diagnostic dilemma for the 1990s: Lyme disease versus rheumatic fever. *Wisconsin Med J* 90:632, 1991.
873. Rath P-M, Rogler G, Schonberg A, et al. Relapsing fever and its serological discrimination from Lyme borreliosis. *Infection* 20:283, 1992.
874. Edlinger E, Rodhain F, Perez C. Lyme disease in patients previously suspected of arbovirus infection. *Lancet* 2:93, 1985.
875. Lader E. Lyme disease misdiagnosed as a temporomandibular joint disorder. *J Prosthet Dent* 63:82, 1990.
876. Meier C, Reulen HJ, Huber P, Mumenthaler M. Meningoradiculoneuritis mimicking vertebral disc herniation. A "neurosurgical" complication of Lyme-borreliosis. *Acta Neurochir* 98:42, 1989.
877. Anonymous. Treatment of Lyme disease. *Med Lett Drugs Ther* 39(1000):47-48, 1997.
878. Dolan MC, Piesman J, Mbow ML, et al. Vector competence of *Ixodes scapularis* and *Ixodes ricinus* (Acari: Ixodidae) for three genospecies of *Borrelia burgdorferi*. *J Med Entomol* 35(4):465-470, 1998.
879. Williams LR, Austin FE. Hemolytic activity of *Borrelia burgdorferi*. *Infect Immun* 60:3224, 1992.
880. Needham GR. Evaluation of five popular methods for tick removal. *Pediatrics* 75:997, 1985.
881. Angelov L, Rakadieva T, Kostova E, Liptchev G. Epidemiology, diagnostics, clinical manifestations, prophylaxis and fight against Lyme borreliosis in Bulgaria. *Folia Med* 37(4A Suppl):94-95, 1995.
882. Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete, *Borrelia burgdorferi*. *Nature* 390:580-586, 1997.
883. Dotevell L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. *Clin Infect Dis* 28:569-574, 1999.
884. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular typing of *Borrelia burgdorferi* sensu lato: Taxonomic, epidemiological, and clinical implications. *Clin Microbiol Rev* 12(4):633-653, 1999.
885. Van Hoecke C, Lebacqz E, Beran J, Parenti D. Alternative vaccination schedules (0, 1, and 6 months) for a recombinant Osp A Lyme disease vaccine. *Clin Infect Dis* 28:1260-1264, 1999.
886. Feder HM, Beran J, Van Hoecke C, et al. Immunogenicity of a recombinant *Borrelia burgdorferi* outer surface membrane protein A vaccine against Lyme disease in children. *J Pediatr* 135:575-579, 1999.
887. American Academy of Pediatrics. Lyme Disease. In: Pickering LK (ed). 2000 Red Book: Report of the Committee on Infectious Diseases, 25th ed. Elk Grove Village, Ill, Amer Acad Pediatr, 2000, 374-379.
888. Logigian EL, Kaplan RE, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. *J Infect Dis* 180:377-383, 1999.